Selected research
Industry Research
Female Infertility Drugs Industry Research Report 2026
Market perspective
The global Female Infertility Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Female Infertility Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Female Infertility Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Female Infertility Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Female Infertility Drugs include Allergan Plc, Ferring BV, Merck KGaA, Novartis AG and Sanofi, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Female Infertility Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Female Infertility Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Female Infertility Drugs Market by Company
Allergan Plc
Ferring BV
Merck KGaA
Novartis AG
Sanofi
Female Infertility Drugs Segment by Type
Parenteral
Oral
Others
Female Infertility Drugs Segment by Application
Low Birth Weight
Multiple-gestation Pregnancies
Multiple-birth Infants
Ovarian Hyperstimulation Syndrome
Risk of Cesarean Delivery
Premature Labor
Female Infertility Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Female Infertility Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Female Infertility Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Female Infertility Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Female Infertility Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Parenteral
- Oral
- Others
Applications
- Low Birth Weight
- Multiple-gestation Pregnancies
- Multiple-birth Infants
- Ovarian Hyperstimulation Syndrome
- Risk of Cesarean Delivery
- Premature Labor
Companies covered
- Allergan Plc
- Ferring BV
- Merck KGaA
- Novartis AG
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Female Infertility Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Parenteral
- 2.2.3 Oral
- 2.2.4 Others
- 2.3 Female Infertility Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Low Birth Weight
- 2.3.3 Multiple-gestation Pregnancies
- 2.3.4 Multiple-birth Infants
- 2.3.5 Ovarian Hyperstimulation Syndrome
- 2.3.6 Risk of Cesarean Delivery
- 2.3.7 Premature Labor
- 2.4 Assumptions and Limitations
3 Female Infertility Drugs Breakdown Data by Type
- 3.1 Global Female Infertility Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Female Infertility Drugs Forecasted Market Size by Type (2027-2032)
4 Female Infertility Drugs Breakdown Data by Application
- 4.1 Global Female Infertility Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Female Infertility Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Female Infertility Drugs Market Perspective (2021-2032)
- 5.2 Global Female Infertility Drugs Growth Trends by Region
- 5.2.1 Global Female Infertility Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Female Infertility Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Female Infertility Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Female Infertility Drugs Market Dynamics
- 5.3.1 Female Infertility Drugs Industry Trends
- 5.3.2 Female Infertility Drugs Market Drivers
- 5.3.3 Female Infertility Drugs Market Challenges
- 5.3.4 Female Infertility Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Female Infertility Drugs Players by Revenue
- 6.1.1 Global Top Female Infertility Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Female Infertility Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Female Infertility Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Female Infertility Drugs Head Office and Area Served
- 6.4 Global Female Infertility Drugs Players, Product Type & Application
- 6.5 Global Female Infertility Drugs Manufacturers Established Date
- 6.6 Global Female Infertility Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Female Infertility Drugs Market Size (2021-2032)
- 7.2 North America Female Infertility Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Female Infertility Drugs Market Size by Country (2021-2026)
- 7.4 North America Female Infertility Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Female Infertility Drugs Market Size (2021-2032)
- 8.2 Europe Female Infertility Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Female Infertility Drugs Market Size by Country (2021-2026)
- 8.4 Europe Female Infertility Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Female Infertility Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Female Infertility Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Female Infertility Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Female Infertility Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Female Infertility Drugs Market Size (2021-2032)
- 10.2 South America Female Infertility Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Female Infertility Drugs Market Size by Country (2021-2026)
- 10.4 South America Female Infertility Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Female Infertility Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Female Infertility Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Female Infertility Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Female Infertility Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Allergan Plc
- 12.1.1 Allergan Plc Company Information
- 12.1.2 Allergan Plc Business Overview
- 12.1.3 Allergan Plc Revenue in Female Infertility Drugs Business (2021-2026)
- 12.1.4 Allergan Plc Female Infertility Drugs Product Portfolio
- 12.1.5 Allergan Plc Recent Developments
- 12.2 Ferring BV
- 12.2.1 Ferring BV Company Information
- 12.2.2 Ferring BV Business Overview
- 12.2.3 Ferring BV Revenue in Female Infertility Drugs Business (2021-2026)
- 12.2.4 Ferring BV Female Infertility Drugs Product Portfolio
- 12.2.5 Ferring BV Recent Developments
- 12.3 Merck KGaA
- 12.3.1 Merck KGaA Company Information
- 12.3.2 Merck KGaA Business Overview
- 12.3.3 Merck KGaA Revenue in Female Infertility Drugs Business (2021-2026)
- 12.3.4 Merck KGaA Female Infertility Drugs Product Portfolio
- 12.3.5 Merck KGaA Recent Developments
- 12.4 Novartis AG
- 12.4.1 Novartis AG Company Information
- 12.4.2 Novartis AG Business Overview
- 12.4.3 Novartis AG Revenue in Female Infertility Drugs Business (2021-2026)
- 12.4.4 Novartis AG Female Infertility Drugs Product Portfolio
- 12.4.5 Novartis AG Recent Developments
- 12.5 Sanofi
- 12.5.1 Sanofi Company Information
- 12.5.2 Sanofi Business Overview
- 12.5.3 Sanofi Revenue in Female Infertility Drugs Business (2021-2026)
- 12.5.4 Sanofi Female Infertility Drugs Product Portfolio
- 12.5.5 Sanofi Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst